154 related articles for article (PubMed ID: 36129951)
1. Predictors for self-discontinuation of anti-osteoporosis medication: A hospital-based real-world study.
Deng YL; Hsu CS; Hsu CY; Chen CH; Ou SF; Liu CF; Yang SH; Shih CH; Chen YM; Lee HT
PLoS One; 2022; 17(9):e0275020. PubMed ID: 36129951
[TBL] [Abstract][Full Text] [Related]
2. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider.
Kyvernitakis I; Kostev K; Kurth A; Albert US; Hadji P
Osteoporos Int; 2014 Dec; 25(12):2721-8. PubMed ID: 25011986
[TBL] [Abstract][Full Text] [Related]
3. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
4. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
[TBL] [Abstract][Full Text] [Related]
5. Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries.
Yun H; Curtis JR; Guo L; Kilgore M; Muntner P; Saag K; Matthews R; Morrisey M; Wright NC; Becker DJ; Delzell E
BMC Musculoskelet Disord; 2014 Apr; 15():112. PubMed ID: 24684864
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Teriparatide and Sequential Antiresorptive Agent Treatment Among Elderly Female Medicare Beneficiaries.
Liu J; Laster A; Xu X; Guo H; Oates M; Gandra SR
J Bone Miner Res; 2021 Dec; 36(12):2309-2316. PubMed ID: 34490946
[TBL] [Abstract][Full Text] [Related]
7. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
8. Role of the Pharmacist in Medication Therapy Management Services in Patients With Osteoporosis.
Murphy-Menezes M
Clin Ther; 2015 Jul; 37(7):1573-86. PubMed ID: 25913920
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide Improves Fracture Healing and Early Functional Recovery in Treatment of Osteoporotic Intertrochanteric Fractures.
Huang TW; Chuang PY; Lin SJ; Lee CY; Huang KC; Shih HN; Lee MS; Hsu RW; Shen WJ
Medicine (Baltimore); 2016 May; 95(19):e3626. PubMed ID: 27175673
[TBL] [Abstract][Full Text] [Related]
10. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
[TBL] [Abstract][Full Text] [Related]
11. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.
Ljunggren Ö; Barrett A; Stoykov I; Langdahl BL; Lems WF; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Karras D; Marin F
BMC Musculoskelet Disord; 2013 Aug; 14():251. PubMed ID: 23968239
[TBL] [Abstract][Full Text] [Related]
12. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
[TBL] [Abstract][Full Text] [Related]
13. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.
Elbers LPB; Raterman HG; Lems WF
Drugs; 2021 Sep; 81(14):1645-1655. PubMed ID: 34524681
[TBL] [Abstract][Full Text] [Related]
14. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
[TBL] [Abstract][Full Text] [Related]
15. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.
van Maren MA; Wyers CE; Driessen JHM; Visser JV; de Vries F; van de Wijdeven K; Gevers S; Lems WF; Emmelot-Vonk MH; van den Bergh JPW
Osteoporos Int; 2019 Sep; 30(9):1837-1844. PubMed ID: 31321446
[TBL] [Abstract][Full Text] [Related]
16. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
[TBL] [Abstract][Full Text] [Related]
17. Treatment and Management of Osteoporotic Fractures: A Nation-wide Survey of 484 Senior Orthopaedists in China.
Man Y; Pan W; Lu J; Li SY; Zhang P; Guo JZ; Yu SF; Zhang B; Xiao E; Zhang C; Zuo W; Jin HJ; Chen Y; Wu B; Shi XE; Hong D; Liu X; Gao YX; Li J; Yin L; Xue QY
Orthop Surg; 2016 Nov; 8(4):432-439. PubMed ID: 28032704
[TBL] [Abstract][Full Text] [Related]
18. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
19. Self-reported calcium use in a cohort of postmenopausal women receiving osteoporosis therapy: results from POSSIBLE US™.
Barrett-Connor E; Wade SW; Downs RW; Ganiats T; Hochberg M; Recker RR; Stolshek BS
Osteoporos Int; 2015 Aug; 26(8):2175-84. PubMed ID: 25876880
[TBL] [Abstract][Full Text] [Related]
20. Effect of improved medication adherence on health care costs in osteoporosis patients.
Cho H; Byun JH; Song I; Kim HY; Ha YC; Kim TY; Lee YK; Jang S
Medicine (Baltimore); 2018 Jul; 97(30):e11470. PubMed ID: 30045269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
